Current and future developments in the use of temozolomide for the treatment of brain tumours.
about
Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and TreatmentPolifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapySalinomycin induced ROS results in abortive autophagy and leads to regulated necrosis in glioblastomaPhase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.The effect of an interdisciplinary rehabilitation intervention comparing HRQoL, symptom burden and physical function among patients with primary glioma: an RCT study protocol.An unusual case of aplastic anemia caused by temozolomideThe use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour ConsortiumPatients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.Proteomic analysis of glioma chemoresistance.O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors.Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.The neuro-steroid, 3beta androstene 17alpha diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathwaysFive-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma.The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agentsExtended survival of Pyk2 or FAK deficient orthotopic glioma xenograftsPhase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131Temozolomide chemotherapy in patients with recurrent malignant gliomas.Pharmacotherapy for adults with tumors of the central nervous system.Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.Treatment of pituitary neoplasms with temozolomide: a review.Therapy of aggressive pituitary tumors.Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.Temozolomide in aggressive pituitary adenomas and carcinomas.Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.Treatment considerations for MGMT-unmethylated glioblastoma.Association of Radiomics and Metabolic Tumor Volumes in Radiation Treatment of Glioblastoma Multiforme.miRNA therapy targeting cancer stem cells: a new paradigm for cancer treatment and prevention of tumor recurrence.E2F transcription factors associated with up-regulated genes in glioblastoma.Advanced interstitial chemotherapy for treating malignant glioma.Novel vaccines for glioblastoma: clinical update and perspective.The tyrosine kinase pyk2 promotes migration and invasion of glioma cells.Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma.A longitudinal, qualitative and quantitative exploration of daily life and need for rehabilitation among patients with high-grade gliomas and their caregivers.
P2860
Q26785952-2C0BCBBD-0E70-4050-8FB8-C9333FF77438Q28078486-29D4BD56-7095-4A32-BAF3-0AD3F09007A0Q28822248-A055D156-7997-4B49-A20B-139303F10A38Q33358912-7A0DFE47-A28C-4D29-860E-099CE97E44ADQ33429765-0A13B742-38FC-4ED7-AC61-BB8E2EBB21EAQ34253705-43CBAA36-D63F-44B7-83BF-C4F058940AD6Q34297703-D37D92C5-149C-4C4F-B6BD-144BC9E42A0BQ34461166-BE38914C-0A8E-42D3-A7A5-E763DD31DA2EQ34541456-E1B264C3-48FB-49CE-B0E1-71A3CF3E117FQ34769937-B2865296-C107-4499-AB8B-45995D0D9B6FQ35177942-D2D829B7-3A4F-49C5-91AF-E2D8AD5AEF6DQ35594029-73F853A5-6CCF-46D5-9835-417A7C87745EQ35778723-8F1FA563-6F0B-4280-8DF7-FC52439B573BQ35844142-A3211EBF-8378-43BA-BCE6-8BBC75C19ED4Q36177805-29F625C7-EEC0-4369-B2AB-01D596505FE4Q36603152-F3ED9F31-7DE0-4E37-BC75-A30F852F9F6FQ36611032-BD71F13D-84B2-4D68-A055-C91D654F42C0Q36732622-A40C8BA7-9067-4416-BDCB-C3697C8B6B6EQ37056618-8E5C465C-F623-42B1-9033-4D7717CF2FD9Q37225907-1654EC52-C93A-430F-AC3C-6600C1217528Q37284303-48DB97C7-F3C6-4F6F-8470-95C6040A6917Q37313220-26495905-6499-423C-A6F2-07A94EE48749Q37353276-5CDA7780-3BBD-4AF5-8945-7998D6F6CA73Q37688272-F23AF0A0-A8CC-497C-8A3F-52DA74F0CEC9Q37789267-8FF7EF0A-686E-4361-85B8-6DD9CCFA71A2Q37857296-F1890067-F312-4A42-A438-FEDA680C8747Q37900207-805B75C9-AFC8-484C-88E1-1CBFD3D0F880Q37953862-E855C049-7B63-41EE-99E6-8AEA2814162FQ37955091-B3B4A09E-7A4E-464D-B40D-9262BAC0E57EQ38010032-34BF30F8-5240-4ED8-95F6-5139F5028118Q38230553-60611F58-3923-4469-9EDD-4D74FDB8E7E6Q38267992-088FE2D3-7342-466C-BA97-394FDB5C054EQ38383169-2C32D16E-C8EF-4197-B2AC-42632D7DFFF2Q38411340-F92DBE17-70F0-4388-8796-BBA6AD5DA0A3Q38725917-406123AC-60DF-4B69-B29F-3C732931FB2BQ38849948-99E02A76-4723-433E-BA40-F7DC594354D8Q39043417-135BD0EE-03EC-4D16-BC46-AFF6279B3E13Q40407170-D4E9D0DD-1033-4947-9E77-CCA777791DE8Q40657080-FF9CBF8E-4A54-45A3-810E-21F06AE00F84Q41789592-1058FCB0-031D-44A8-AF1B-A3D1AE11B206
P2860
Current and future developments in the use of temozolomide for the treatment of brain tumours.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Current and future development ...... he treatment of brain tumours.
@ast
Current and future development ...... he treatment of brain tumours.
@en
Current and future development ...... he treatment of brain tumours.
@nl
type
label
Current and future development ...... he treatment of brain tumours.
@ast
Current and future development ...... he treatment of brain tumours.
@en
Current and future development ...... he treatment of brain tumours.
@nl
prefLabel
Current and future development ...... he treatment of brain tumours.
@ast
Current and future development ...... he treatment of brain tumours.
@en
Current and future development ...... he treatment of brain tumours.
@nl
P2093
P1433
P1476
Current and future development ...... he treatment of brain tumours.
@en
P2093
P304
P356
10.1016/S1470-2045(01)00489-2
P577
2001-09-01T00:00:00Z